Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

Impact · against what's priced in

The launch of denosumab biosimilars in Canada introduces new competitive pressure for Amgen and opens a new revenue stream for Organon and Henlius. While typically a negative for the brand owner, the impact is localized to the Canadian market.

OGN+0.20

No priced-in read yet